Pharnext Presents a Business Update Webcast on May 20th, 2020
PARIS, France, 6:00 pm, May 14, 2020 (CET) – Pharnext SA (FR0011191287 - ALPHA), an advanced clinical-stage biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on big genomic data and artificial intelligence, today confirmed the organization of a webcast to update on its current activities on May 20th, 2020 at 6:00 pm (CET).
During this webcast, David Horn Solomon, Chief Executive Officer, will provide a business update and overview of Pharnext.
Attendees can participate by weblink: https://channel.royalcast.com/webcast/pharnext/20200520_1/
or connect by phone using the following coordinates:
Confirmation Code: Pharnext
Dials-in:
- USA: +1 212 999 6659
- France: +33 (0) 1 7099 4740
- UK: +44 (0) 20 3003 2666
About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase 3 trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated encouraging Phase 2 results in Alzheimer’s disease. Pharnext has developed a new drug discovery paradigm based on big genomic data and artificial intelligence: PLEOTHERAPY™. Pharnext identifies and develops synergic combinations of drugs called PLEODRUG™. The Company was founded by renowned scientists and entrepreneurs, including Professor Daniel Cohen, pioneer in modern genomics, and is supported by a world-class scientific team. More information at www.pharnext.com.
Pharnext is listed on the Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).
